Abstract

NOTARIO DONGIL, C et al. CAR-T: lights and shades. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.4, pp.329-333.  Epub May 25, 2021. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2020000400005.

Adoptive cell therapy is revolutionizing the current therapeutic landscape. The management of CAR-T drugs is a challenge for The National Health System (NHS), as they are complex drugs with high impact on health. This way, the development of clinical pharmaceutical protocols with clearly defined criteria, will help in correct positioning and selection of patients candidates for these therapies. Likewise, administration of these drugs must be carried out in centers previously selected and qualified for this purpose, guaranteeing equity of access. On the other hand, a multidisciplinary approach of all patients treated with CAR-T therapies is a priority. Finally, the assessment and the constant result recording are essencial, since they will contribute to determining the real benefit of these therapies, claiming the need for equitable prices, guaranteeing the sustainability of the NHS and the access of previously selected patients to them.

Keywords : Adoptive immunotherapy; health impact assessment; CD19-specific chimeric antigen receptor; adverse effects; tisagenlecleucel; axicabtagene ciloleucel.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )